Positive predictive value of 99mtc sestamibi scintimammography in patients with non-palpable, mammographically detected, suspicious, breast lesions

Nuclear Medicine Communications

Volumn 23, Issue 11, 2002, Pages 1073-1078

  Lumachi, F ^a   Zucchetta, P ^a   Marzola, M C ^b   Ferretti, G ^b   Povolato, M ^b   Paris, M K ^c   Brandes, A A ^c   Bui, F ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b Nuclear Medicine Service   (United States)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Breast cancer; Mammography; Positive predictive value; Scintimammography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TETROFOSMIN TC 99M; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST DISEASE; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTICENTER STUDY; NEEDLE BIOPSY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; SCINTILLATION CAMERA; SCINTIMAMMOGRAPHY; STEREOTAXIC SURGERY; TUMOR VOLUME; AGE; BREAST TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; LABORATORY DIAGNOSIS; METHODOLOGY; MIDDLE AGED; PALPATION; PATHOLOGY; POSTMENOPAUSE; PREDICTION AND FORECASTING; PREMENOPAUSE; RADIOGRAPHY; SCINTISCANNING;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; PALPATION; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0036854424     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200211000-00006     Document Type: Article

References (40)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6-29.
2. Jensen OM, Esteve J, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 26: 1167-1256.
3. Lumachi F, Marzola MC, Zucchetta P, et al. Breast cancer detection with 99m-Tc-sestamibi scintigraphy, mammography, and fine-needle aspiration cytology: comparative study in 64 surgically treated patients. Ann Surg Oncol 1999; 6: 568-571.
4. Dierks DB, Katy B. Lawsuits for failure to diagnose breast cancer: tumor biology in causation and risk management strategies. Surg Oncol North Am 1994; 3: 125-139.
5. Goldenberg DM, Nabi HA. Breast cancer imaging with radiolabeled antibodies. Semin Nucl Med 1999; 29: 41-48.
6. Bone B, Pentek Z, Perbeck L, et al. Diagnostic accuracy of mammography and contrast-enhanced MR imaging in 238 histologically verified breast lesions. Acta Radiol 1997; 38: 489-496.
7. Bird RE, Wallace TW, Yankaskas BC. Analysis of cancers missed at the screening mammography. Radiology 1992; 84: 613-617.
8. Kopans DB. The positive predictive value of mammography. Am J Roentgenol 1992; 158: 521-526.
9. Burrell HC, Pinder SE, Wilson AR, et al. The positive predictive value of mammographic signs: a review of425 non-palpable breast lesions. Clin Radiol 1996; 51: 277-281.
10. Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mammograms and clinical breast examination. N Engl J Med 1998; 338: 1089-1096.
11. Fiorica JV. Breast cancer. In: Leppert PC, Howard FM, eds. Primary care for women. Philadelphia, USA: Lippincot-Raven, 1997: 198-202.
12. Narod SA. On being the right size: a reappraisal of mammography trials in Canada and Sweden. Lancet 1997; 349: 1846.
13. 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med 1999; 29: 16-40.
14. American College of Radiology. Breast imaging reporting and data system (BI-RADS). Reston, USA: American College of Radiology, 1993.
15. Khalkhali I, Diggles LE, Taillefer R, et al. Procedure guideline for breast scintigraphy. J Nucl Med 1999; 40: 1233-1235.
16. Lumachi F, Ferretti G, Povolato M, et al. Accuracy of technetium-99m sestamibi scintimammography and X-ray mammography in premenopausal women with suspected breast cancer. Eur J Nucl Med 2001; 28: 1776-1780.
17. Jackson VP, Hendrick RE, Feig SA, et al. Imaging of the radiographically dense breast. Radiology 1993; 188: 297-301.
18. Douek M, Davidson T, Taylor I. Breast cancer imaging - what are the optimal modalities? Eur J Surg Oncol 1998; 24: 573-582.
19. Soo MS, Rosen EL, Baker JA, Vo TT, Boyd BA. Negative predictive value of sonography with mammography in patients with palpable breast lesions. Am J Roentgenol 2001; 177: 1167-1170.
20. 99mTc-sestamibi scintimammography and sonography in the diagnostic workup of breast masses. Am J Roentgenol 2001; 174: 1779-1783.
21. Hon CK, Schiepers C. 18-FDG imaging in breast cancer. Semin Nucl Med 1999; 29: 49-56.
22. Palmedo H, Bender H, Grünwald F, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 1997; 24: 1138-1145.
23. Tiling R, Sommer H, Pechmann M, et al. Comparison of technetium-99m-sestamibi scintimammography with contrast-enhanced MRI for diagnosis of breast lesions. J Nucl Med 1997; 38: 58-62.
24. Helbich TH, Becherer A, Tratting S, et al. Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi scintimammography. Radiology 1997; 202: 421-429.
25. Hrung JM, Sonnad SS, Schwartz JS, et al. Accuracy of MR imaging in the work-up of suspicious breast lesions: a diagnostic meta-analysis. Acad Radiol 1999; 6: 387-397.
26. Tan JE, Orel SG, Schnall MD, et al. Role of magnetic resonance imaging and magnetic resonance imaging-guided surgery in the evaluation of patients with early-stage breast cancer for breast conservation treatment. Am J Clin Oncol 1999; 22: 414-418.
27. 99mTc-MIBI scintimammography for the detection of breast malignancies: the contribution of the count ratio to specificity. Nucl Med Commun 1999; 20: 511-516.
28. 99mTc-sestamibi breast imaging: multicenter trial results. J Nucl Med 2000; 41: 1973-1979.
29. Sampalis FS, Denis R, Picard D, et al. International prospective evaluation of scintimammography with technetium-99m sestamibi: interim results. Am J Surg 2001; 182: 399-403.
30. Lumachi F, Ferretti G, Povolato M, et al. Sestamibi scintimammography in pT1 breast cancer: alternative or complementary to X-ray mammography? Anticancer Res 2001; 21: 2201-2205.
31. m-MIBI. Nucl Med Commun 2001; 22: 807-811.
32. 99mTc-scintimammography in suspected breast cancer. J Nucl Med 1999; 40: 296-301.
33. Uriarte I, Carril JM, Quirce R, et al. Optimization of X-ray mammography and technetium-99m methoxyisobutylisonitrile scintimammography in the diagnosis of non-palpable breast lesions. Eur J Nucl Med 1998; 25: 491-496.
34. Smith LN, Klimberg VS. Is scintimammography really the most valuable preoperative assessment tool? Ann Surg Oncol 1999; 6: 525-527.
35. Drew PJ, Chatterjee S, Turnbull LW, et al. Dynamic contrast enhanced magnetic resonance imaging of the breast is superior to triple assessment for the pre-operative detection of multifocal breast cancer. Ann Surg Oncol 1999; 6: 599-603.
36. Vaidya JS, Vyas J, Chinoy RF, et al. Multicentricity of breast cancer: whole organ analysis and clinical implications. Br J Cancer 1996; 74: 820-824.
37. Douek M, Vaidya JS, Lakhani SR, et al. Can magnetic resonance imaging help elucidate natural history of breast cancer multicentricity? Lancet 1998; 351: 801-802.
38. 99mTc-MIBI identify multifocal and multicentric primary breast cancer? Nucl Med Commun 2001; 22: 1287-1293.
39. 99mTc-sestamibi scintimammography complementary to conventional mammography for detecting breast cancer in patients with palpable masses? J Nucl Med 2001; 42: 1614-1621.
40. Buscombe JR, Cwikla JB, Holloway B, Hilston AJ. Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves. J Nucl Med 2001; 42: 3-8.